Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
02 Oktober 2023 - 10:52PM
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology
company dedicated to enabling normal lives for people with
autoimmune diseases, today announced the closing of its previously
announced underwritten public offering of 8,475,500 shares of its
common stock at a price of $38.00 per share. This includes the
exercise in full by the underwriters of their option to purchase up
to 1,105,500 additional shares of common stock. Concurrent with the
public offering, Immunovant sold 4,473,684 shares of common stock
to Roivant Sciences, Ltd. at a price of $38.00 per share in a
private placement exempt from the registration requirements of the
Securities Act of 1933, as amended, or the Securities Act. The
aggregate gross proceeds to Immunovant from the public offering and
concurrent private placement were approximately $492.1 million,
before deducting underwriting discounts and commissions, placement
agent fees and offering expenses payable by Immunovant.
Leerink Partners, Piper Sandler, Guggenheim Securities and Wells
Fargo Securities acted as joint bookrunning managers for the public
offering. LifeSci Capital acted as co-manager for the public
offering.
The shares in the public offering were offered by Immunovant
pursuant to a Registration Statement on Form S-3 previously filed
and declared effective by the SEC. A final prospectus supplement
related to the public offering was filed with the SEC on September
29, 2023 and is available on the SEC’s website located at
www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to the public offering may also be obtained
from: Leerink Partners LLC, Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525
ext. 6105, or by email at syndicate@leerink.com; Piper Sandler
& Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, Minnesota 55402, or by telephone at (800)
747-3924, or by email at prospectus@psc.com; Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
8th Floor, New York, NY 10017, or by telephone at (212) 518-9544,
or by email at GSEquityProspectusDelivery@guggenheimpartners.com;
and Wells Fargo Securities, LLC, Attention: Equity Syndicate
Department, 500 West 33rd Street - 14th Floor, New York, NY 10001,
or by telephone at (800) 645-3751, or by email at
WFScustomerservice@wellsfargo.com.
The shares of common stock sold in the concurrent private
placement have not been registered under the Securities Act or
under any state securities laws and, unless so registered may not
be offered or sold in the United States except pursuant to an
exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable
state securities laws.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy, nor will there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation, or sale would be unlawful before registration
or qualification under the securities laws of that state or
jurisdiction.
Contact:Chau Cheng, PhD MBAVice President,
Investor RelationsImmunovant, Inc.info@immunovant.com
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024